Article
The role of FLT3 kinase as an AML therapy target.
Current pharmaceutical design - 1 Jan 2012
Beffinger Michał, Skwarska Anna
Abstract excerpt
FMS-like tyrosine kinase-3 (FLT3) is a tyrosine kinase receptor involved in the survival and expansion of hematopoietic stem progenitors. A constitutively activated, mutated form of FLT3, is expressed in approximately 30% of de novo acute myeloid leukemia (AML) and about 6% of acute lymphoblastic leukemia (ALL) cases. Since mutant FLT3 has emerged as an attractive therapeutic target, there are several FLT3...
Topics
- Antineoplastic Agents
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- fms-Like Tyrosine Kinase 3